We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How investigators and sponsors should manage clinical trials during COVID-19
More information following our investigation into an increase of adverse event reports following the cascade use of intravenous co-amoxiclav (amoxicillin and clavulanic acid) products.
Who you should contact if a pet or other animal or human has an unexpected reaction to a veterinary medicine or a problem with a microchip
Awareness and action regarding increase of suspected adverse event reports following use of intravenous co-amoxiclav (amoxicillin and clavulanic acid) products.
Healthcare professionals should be vigilant for suspected adverse reactions and safety concerns associated with e-cigarettes and e-liquids, commonly known as vapes. Please report adverse reactions to the Yellow Card scheme and promote vigilance among patients.
Details of the Yellow Card scheme, which is the system for recording adverse incidents with medicines and medical devices in the UK.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.